After Zavante deal, Nabriva is poised to launch two first-in-class antibiotics
On July 24, Nabriva Therapeutics announced the acquisition of Zavante Therapeutics, a biotechnology...
Trending:
-
![]()
EMA gives PRIME status to promising Huntington’s treatment
-
![brexit]()
UK seeks harmony with EU CTR as NHS and pharma stockpile drugs
-
![]()
Big soil: Genentech and Lodo launch $1bn project to develop new drugs from earth
-
![]()
Pfizer/Lilly’s Phase III trial for tanezumab in osteoarthritis still draws caution
-
![]()
Survey shows pharma’s doubts over Brexit outcome
-
![]()
Achillion’s C3G trial earmarked for success, despite slow recruitment
Most Read
- Realm Therapeutics unveils phase II failure of PR022 for severe eczema
- Janssen and ViiV report positive results for two drug regimen for HIV-1
- Big soil: Genentech and Lodo launch $1bn project to develop new drugs from earth
- Could cutting out mediators let cancer research off the leash?
- Study shows methylphenidate is most effective ADHD drug for under-16s
Company A-Z
Latest Content
After Zavante deal, Nabriva is poised to launch two first-in-class antibiotics
On July 24, Nabriva Therapeutics announced the acquisition of Zavante Therapeutics, a biotechnology company developing treatments for the infections that threaten hospitalized patients.
Fasinumab Phase III osteoarthritis trial meets endpoints
Teva Pharmaceutical and Regeneron Pharmaceuticals have reported positive top-line data from a phase III clinical trial of fasinumab to treat chronic pain in patients with osteoarthritis (OA) of the knee or hip.
EMA gives PRIME status to promising Huntington’s treatment
PRIME is the European Medicines Agency (EMA) Priority Medicines scheme to support the development of medicines that meet a high unmet need.
UK seeks harmony with EU CTR as NHS and pharma stockpile drugs
The Medicines Health Products Regulatory Agency has reaffirmed its commitment to follow the European Clinical Trials Regulation System (CTR) during the Brexit transition period, between March 2019 and December 2020.
Realm Therapeutics unveils phase II failure of PR022 for severe eczema
US-based Realm Therapeutics has announced its drug candidate PR022 for atopic dermatitis has failed to achieve its primary endpoint in a phase II trial.
Janssen and ViiV report positive results for two drug regimen for HIV-1
Johnson & Johnson subsidiary Janseen Pharmaceuticals and ViiV Healthcare have reported positive topline results from their phase III trial of an investigational long-acting injectable two drug regimen for the treatment of human immunodeficiency virus-1 (HIV-1).
US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment
The US Food & Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) by Motif Bio for iclaprim, which is a targeted, Gram-positive investigational antibiotic, indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Big soil: Genentech and Lodo launch $1bn project to develop new drugs from earth
Genentech has signed a $1bn open-ended drug discovery collaboration with Lodo Therapeutics to develop unique, natural products from the microbial DNA found in soil. Genentech will use Lodo’s metagenome-prospecting platform to identify novel small molecules with the potential for treating disease. With this level of investment confidence must be high, but just how much potential lies in soil, and how can it be harnessed?
Gerresheimer at Medtec China
Gerresheimer develops and produces innovative drug delivery systems and medical and diagnostic products for prestigious international customers.
Pfizer/Lilly’s Phase III trial for tanezumab in osteoarthritis still draws caution
Pfizer and Eli Lilly’s tanezumab for osteoarthritis (OA) of the hip and knee may face hurdles to clear long-term efficacy and safety benchmarks.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
